Express News | HC Wainwright & Co. Reiterates Buy on Esperion Therapeutics, Maintains $16 Price Target
Express News | Esperion Therapeutics Inc : BofA Global Research Cuts Price Objective to $1.85 From $2
Press Release: Esperion to Report First Quarter 2025 Financial Results on May 6
Esperion Therapeutics Inc (ESPR) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ...
Express News | Esperion Therapeutics Inc Files for Mixed Shelf of up to $400 Mln- SEC Filing
Esperion Therapeutics Is Maintained at Neutral by Goldman Sachs
Goldman Sachs Maintains Esperion Therapeutics(ESPR.US) With Hold Rating, Cuts Target Price to $3
AI replacing animal experiments? A message from the FDA has left "monkey breeders" feeling devastated, and experts state that "we are still far from the stage of implementation."
① The news that the USA FDA has publicly stated it will gradually replace animal testing requirements has led to an increase in the stock prices of AI pharmaceutical companies, impacting traditional drug evaluation CRO companies; ② Some believe this action represents a trend in Industry development. However, others believe that it is far from being implementable.
Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025
Needham Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $5
Esperion Therapeutics Price Target Maintained With a $5.00/Share by Needham
Esperion Therapeutics (ESPR) Down 15.8% Since Last Earnings Report: Can It Rebound?
Esperion Therapeutics: Nicole Vitullo, Antonio Gotto to Step Down From June 1 >ESPR
Esperion Therapeutics: Hoffman's Appointment Effective Immediately >ESPR
Express News | Esperion Appoints Robert E. Hoffman to Board of Directors
Press Release: Esperion Appoints Robert E. Hoffman to Board of Directors
Esperion to Participate in 24th Annual Needham Virtual Healthcare Conference
H.C. Wainwright Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $16
Express News | Esperion Therapeutics Inc - to Initiate Phase 3 Clinical Studies This Year
Esperion Aligns With U.S. Food and Drug Administration to Initiate Phase 3 Clinical Trials of Bempedoic Acid in Pediatric Heterozygous and Homozygous Familial Hypercholesterolemia